12
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis

, , , &
Pages 398-402 | Received 06 Apr 2007, Accepted 01 Jun 2007, Published online: 02 Jan 2014

References

  • Cronstein BN. Molecular therapeutics: methotrexate and its mech-anism of action. Arthritis Rheum 1996;39:1951–60.
  • Widemann BC, Balls FM, Adamson PC. Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader. Clin Chem 1999;45: 223–8.
  • Oktem F, Yilmaz HR, Ozguner F, Olgar S, Ayata A, Uzare E, et al. Methotrexate-induced renal oxidative stress in rats: the role of a novel antioxidant caffeic acid phenethyl ester. Toxicol Ind Health 2006;22:241–7.
  • Devrim E, Cetin R, Kilicoglu B, Erguder BI, Avci A, Durak I. Methotrexate causes oxidative stress in rat kidney tissues. Ren Fail 2005;27:771–3.
  • Huang CC, Hsu PC, Hung YC, Liao YF, Liu CC, Hour CT, et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis 2005;10:895–907.
  • Sung JY, Hong JH, Kang HS, Choi I, Lim SD, Lee JK, et al. Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology 2000;47:35–44.
  • Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthritis. Arthritis Res Ther 2004;6:265–78.
  • Halliwell B. Oxygen radicals, nitric oxide and human inflammatory joint disease. Ann Rheum Dis 1995;54:505–10.
  • Biemond P, Swaak AJ, Koster JE Protective factors against oxygen free radicals and hydrogen peroxide in rheumatoid arthritis syno-vial fluid. Arthritis Rheum 1984;27:760–5.
  • Takahashi M, Ohishi T, Aoshima H, Kawana K, Kushida K, Inoue T, et al. The Maillard protein cross-link pentosidine in urine from diabetic patients. Diabetologia 1993;36:664–7.
  • Jikimoto T, Nishikubo Y, Koshiba M, Kanagawa S, Morinobu S, Morinobu A, et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 2002;38: 765–72.
  • Takahashi M, Hoshino H, Kushida K, Inoue T. Direct measure-ment of crosslinks, pyridinoline, deoxypyridinoline, and pentosi-dine, in the hydrolysate of tissues using high-performance liquid chromatography. Anal Biochem 1995;232:158–62.
  • Torikai E, Kageyama Y, Takahashi M, Nagano A. The effect of methotrexate on bone metabolism markers in patients with rheu-matoid arthritis. Mod Ftheumatol 2006;16:350–4.
  • Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006;58:473–92.
  • Genestier L, Paillot R, Foumel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Chin Invest 1998; 15;102:322–8.
  • Paillot R, Genestier L, Fournel S, Ferraro C, Miossec P, Revillard JP. Activation-dependent lymphocyte apoptosis induced by meth-otrexate. Transplant Proc 1998;30:2348–50.
  • Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, et al. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Ftheumatol 1995;34: 602–9.
  • O'Callaghan JW, Forrest MJ, Brooks PM. Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients. Ftheumatol Int 1988;8:41–5.
  • Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729–35.
  • Kumar DA, Raju KV, Settu K, Kumanan K, Puvanakrishnan R. Effect of a derivatized tetrapeptide from lactoferrin on nitric oxide mediated matrix metalloproteinase-2 production by synovial fibro-blasts in collagen-induced arthritis in rats. Peptides 2006;27: 1434–42.
  • Winrow VR, Winyard PG, Morris CJ, Blake DR. Free radicals in inflammation: second messengers and mediators of tissue destruc-tion. Br Med Bull 1993;49:506–22.
  • Mapp PI, Grootveld MC, Blake DR. Hypoxia, oxidative stress and rheumatoid arthritis. Br Med Bull 1995;51:419–36.
  • Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR. Oxygen-derived free radicals stimulate osteodastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990;85:632–9.
  • Box BE, Alam AS, Banerji B, Box CM, Bevis PJ, Stevens CR, et al. Stimulation of osteoclastic bone resorption by hydrogen per-oxide. Biochem Biophys Res Commun 1992;183:1153–8.
  • Woo CH, Kim TH, Choi JA, Ryu HC, Lee JE, You HJ, et al. Inhibition of receptor internalization attenuates the TNF alpha-induced ROS generation in non-phagocytic cells. Biochem Biophys Res Commun 2006;351:972–78.
  • Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y, et al. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMB 0 J 2003;22: 3898–909.
  • Halliwell B, Hoult JR, Blake DR. Oxidants, inflammation, and anti-inflammatory drugs. FASEB J 1988;2:2867–73.
  • Takahashi M. Pentosidine, an advanced glycation end-product, and arthritis. Curr Ftheumatol Rev 2006;2:319–24.
  • Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutro-phils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein: a mechanism for the generation of highly reactive alpha-hydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 1997;99:424–32.
  • Takahashi M, Kushida K, Ohishi T, Kawana K, Hoshino H, Uchi-yama A, et al. Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Arthritis Rheum 1994;37:724–8.
  • Hofmann MA, Schiekofer S, Isermann B, Kanitz M, HenkeIs M, Joswig M, et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Dia-betologia 1999;42:222–32.
  • Daoud S, Schinzel R, Neumann A, Loske C, Fraccarollo D, Diez C, Simm A. Advanced glycation endproducts: activators of cardiac remodeling in primary fibroblasts from adult rat hearts. Mol Med 2001;7:543–51.
  • Hein GE, Kohler M, Oelzner P, Stein G, Franke S. Theadvanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Ftheumatol Int 2005;26: 137–41.
  • Takagi M, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, et al. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res 1997;12:439–46.
  • Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240: 1546–8.
  • Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induc-tion of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90:439–46.
  • Schmidt AM, Hon i 0, Chen JX, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995;96: 1395–403.
  • Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 1998;9: 1681–8.
  • Bjorgaas M, Haug E, Johnsen HJ. The urinary excretion of deoxy-pyridinium cross-links is higher in diabetic than in nondiabetic adolescents. Calcif Tissue Int 1999;65:121–4.
  • Schraufstatter IU, Hyslop PA, Jackson JH, Cochrane CG. Oxidant-induced DNA damage of target cells. J Chin Invest 1988; 82:1040–50.
  • Kasai H, Crain PF, Kuchino Y, Nishimura S, Ootsuyama A, Tanooka H. Formation of 8-hydroxyguanine moiety in cellular DNA by agents producing oxygen radicals and evidence for its repair. Carcinogenesis (Lond) 1986;7:1849–51.
  • Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999;49:91–102.
  • Erhola M, Toyokuni S, Okada K, Tanaka T, Hiai H, Ochi H, et al. Biomarker evidence of DNA oxidation in lung cancer patients: association of urinary 8-hydroxy-2'-deoxyguanosine excretion with radiotherapy, chemotherapy, and response to treatment. FEBS Lett 1997;409:287–91.
  • Honda M, Yamada Y, Tomonaga M, Ichinose H, Kamihira S. Correlation of urinary 8-hydroxy-2'-deoxyguanosine (8–0HdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study. Leuk Res 2000;24: 461–8.
  • Kim JY, Mukherjee S, Ngo LC, Christiani DC. Urinary 8-hydroxy-2'-deoxyguanosine as a biomarker of oxidative DNA damage in workers exposed to fine particulates. Environ Health Perspect 2004;112:666–71.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.